Ionis Pharmaceuticals initiated with a Neutral at Redburn Atlantic
Redburn Atlantic analyst Joshua Smith initiated coverage of Ionis Pharmaceuticals (IONS) with a Neutral rating and $39 price target Ionis is a ...